Boston NPR Health Blog Highlights CF Drug Development
| 1 min read

A story featured on Boston's NPR blog CommonHealth spotlights recent progress made in cystic fibrosis drug development. 

The blog post focuses on new treatments developed by Vertex Pharmaceuticals Inc. in collaboration with the Cystic Fibrosis Foundation that target the underlying cause of CF, and highlights the recent FDA approval of Kalydeco. Robert J. Beall, Ph.D., president and CEO of the CF Foundation, is quoted: “The improvement that we're seeing with Kalydeco is so much more than we see with any other intervention we've ever had.”

Also highlighted are recent positive results from a Phase 2 combination study of Kalydeco and VX-809. The combination therapy could potentially help 27-year-old Danny Bessette, who was featured on the cover of Science magazine when the CF gene was discovered in 1989. Bessette remains hopeful as the treatment moves toward a Phase III clinical trial.

Read the full story.

Share this article
About the CF Foundation | Drug Pipeline
Recent news
CF Foundation Invests Up to $3 Million in ViaNautis Bio to Explore a New Method to Deliver Genetic Therapies to People With CF
News | 2 min read
CF Foundation Formalizes Final Set of Recommendations From External Racial Justice Working Group
News | 4 min read
CF Foundation Awards Advance Improvements in CF Newborn Screening
News | 4 min read
You might also be interested in...
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.